This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (273)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Randomized Controlled Trial  • Drug Therapy, Other  • Alert me on articles by topic

A Randomized Controlled Trial

Vivian Fonseca, MD; Julio Rosenstock, MD; Rita Patwardhan, PhD; Alan Salzman, MD, PhD

JAMA. 2000;283:1695-1702.

Context  Most antidiabetic agents target only 1 of several underlying causes of diabetes. The complementary actions of the antidiabetic agents metformin hydrochloride and rosiglitazone maleate may maintain optimal glycemic control in patients with type 2 diabetes; therefore, their combined use may be indicated for patients whose diabetes is poorly controlled by metformin alone.

Objective  To evaluate the efficacy of metformin-rosiglitazone therapy in patients whose type 2 diabetes is inadequately controlled with metformin alone.

Design  Randomized, double-blind, placebo-controlled trial from April 1997 and March 1998.

Setting  Thirty-six outpatient centers in the United States.

Patients  Three hundred forty-eight patients aged 40 to 80 years with a mean fasting plasma glucose level of 12.0 mmol/L (216 mg/dL), a mean glycosylated hemoglobin level of 8.8%, and a mean body mass index of 30.1 kg/m² were randomized.

Interventions  Patients were assigned to receive 2.5 g/d of metformin plus placebo (n = 116); 2.5 g/d of metformin plus 4 mg/d of rosiglitazone (n = 119); or 2.5 g/d of metformin and 8 mg/d of rosiglitazone (n = 113) for 26 weeks.

Main Outcome Measures  Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin sensitivity, and -cell function, compared between baseline and week 26, by treatment group.

Results  Glycosylated hemoglobin levels, fasting plasma glucose levels, insulin sensitivity, and -cell function improved significantly with metformin-rosiglitazone therapy in a dose-dependent manner. The mean levels of glycosylated hemoglobin decreased by 1.0% in the 4 mg/d metformin-rosiglitazone group and by 1.2% in the 8 mg/d metformin-rosiglitazone group and fasting plasma glucose levels by 2.2 mmol/L (39.8 mg/dL) and 2.9 mmol/L (52.9 mg/dL) compared with the metformin-placebo group (P<.001 for all). Of patients receiving 8 mg/d of metformin-rosiglitazone, 28.1% achieved a glycosylated hemoglobin level of 7% or less. Dose-dependent increases in body weight and total and low-density lipoprotein cholesterol levels were observed (P<.001 for both rosiglitazone groups vs placebo). The proportion of patients reporting adverse experiences was comparable across all groups.

Conclusions  Our data suggest that combination treatment with once-daily metformin-rosiglitazone improves glycemic control, insulin sensitivity, and -cell function more effectively than treatment with metformin alone.

Author Affiliations: Department of Medicine, Endocrinology Section, Tulane University, New Orleans, La (Dr Fonseca); Dallas Diabetes Center, Dallas, Tex (Dr Rosenstock); Departments of Biometrics (Dr Patwardhan) and Clinical Research and Development (Dr Salzman), SmithKline Beecham Pharmaceuticals, Collegeville, Pa.

RELATED ARTICLE

April 5, 2000
JAMA. 2000;283(13):1759-1760.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Interaction of Oral Antidiabetic Drugs With Hepatic Uptake Transporters: Focus on Organic Anion Transporting Polypeptides and Organic Cation Transporter 1
Bachmakov et al.
Diabetes 2008;57:1463-1469.
ABSTRACT | FULL TEXT  

Population Exposure-Response Modeling of Metformin in Patients With Type 2 Diabetes Mellitus
Hong et al.
J Clin Pharmacol 2008;48:696-707.
ABSTRACT | FULL TEXT  

Dissociation between the Insulin-Sensitizing Effect of Rosiglitazone and Its Effect on Hepatic and Intestinal Lipoprotein Production
Duez et al.
J. Clin. Endocrinol. Metab. 2008;93:1722-1729.
ABSTRACT | FULL TEXT  

Inclusion of Biomarkers for Detecting Perturbations in the Heart and Lung and Lipid/Carbohydrate Metabolism in National Toxicology Program Studies
Dunnick et al.
Toxicol Sci 2007;100:29-35.
ABSTRACT | FULL TEXT  

Easing the Transition to Insulin Therapy in People With Type 2 Diabetes
Blonde
The Diabetes Educator 2007;33:232S-240S.
FULL TEXT  

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen and Wolski
NEJM 2007;356:2457-2471.
ABSTRACT | FULL TEXT  

Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248-255
Karalliedde and Viberti
Diabetes 2007;56:e3-e3.
FULL TEXT  

The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Zinman et al.
ANN INTERN MED 2007;146:477-485.
ABSTRACT | FULL TEXT  

{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg
Endocr. Rev. 2007;28:187-218.
ABSTRACT | FULL TEXT  

Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Bosi et al.
Diabetes Care 2007;30:890-895.
ABSTRACT | FULL TEXT  

A 74-Year-Old Woman With Diabetes
Abrahamson
JAMA 2007;297:196-204.
ABSTRACT | FULL TEXT  

Effect of Various Diuretic Treatments on Rosiglitazone-Induced Fluid Retention
Karalliedde et al.
J. Am. Soc. Nephrol. 2006;17:3482-3490.
ABSTRACT | FULL TEXT  

Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
Shim et al.
Eur J Endocrinol 2006;155:615-622.
ABSTRACT | FULL TEXT  

Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan et al.
Diabetes Care 2006;29:1963-1972.
FULL TEXT  

Effects of Rosiglitazone on Lipids, Adipokines, and Inflammatory Markers in Nondiabetic Patients With Low High-Density Lipoprotein Cholesterol and Metabolic Syndrome
Samaha et al.
Arterioscler. Thromb. Vasc. Bio. 2006;26:624-630.
ABSTRACT | FULL TEXT  

Acute pulmonary edema due to rosiglitazone use in a patient with diabetes mellitus.
Cekmen et al.
J Intensive Care Med 2006;21:47-50.
ABSTRACT  

Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome
Cataldo et al.
Hum Reprod 2006;21:109-120.
ABSTRACT | FULL TEXT  

Insulin-Sensitizing Antihyperglycemic Drugs and Mortality After Acute Myocardial Infarction: Insights from the National Heart Care Project
Inzucchi et al.
Diabetes Care 2005;28:1680-1689.
ABSTRACT | FULL TEXT  

Effects of a medication assistance program on health outcomes in patients with type 2 diabetes mellitus
Strum et al.
Am J Health Syst Pharm 2005;62:1048-1052.
ABSTRACT | FULL TEXT  

Effects of Metformin and Rosiglitazone Treatment on Insulin Signaling and Glucose Uptake in Patients With Newly Diagnosed Type 2 Diabetes: A Randomized Controlled Study
Karlsson et al.
Diabetes 2005;54:1459-1467.
ABSTRACT | FULL TEXT  

ADA Offers Practitioners Crash Course in Diabetes Management
Esposito
DOC News 2005;2:10-10.
FULL TEXT  

Oral Agents for Type 2 Diabetes: An Update
Kimmel and Inzucchi
Clin. Diabetes 2005;23:64-76.
ABSTRACT | FULL TEXT  

Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
Masoudi et al.
Circulation 2005;111:583-590.
ABSTRACT | FULL TEXT  

Rosiglitazone, But Not Glyburide, Reduces Circulating Proinsulin and the Proinsulin:Insulin Ratio in Type 2 Diabetes
Smith et al.
J. Clin. Endocrinol. Metab. 2004;89:6048-6053.
ABSTRACT | FULL TEXT  

Severe Hypo-{alpha}-Lipoproteinemia During Treatment With Rosiglitazone
Sarker et al.
Diabetes Care 2004;27:2577-2580.
ABSTRACT | FULL TEXT  

Effect of Rosiglitazone Versus Insulin on the Pancreatic {beta}-Cell Function of Subjects With Type 2 Diabetes
Ovalle and Bell
Diabetes Care 2004;27:2585-2589.
ABSTRACT | FULL TEXT  

A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette et al.
Arch Intern Med 2004;164:2097-2104.
ABSTRACT | FULL TEXT  

Thiazolidinediones
Yki-Jarvinen
NEJM 2004;351:1106-1118.
FULL TEXT  

Hormone Therapy Impairs Endothelial Function in Postmenopausal Women with Type 2 Diabetes Mellitus Treated with Rosiglitazone
Honisett et al.
J. Clin. Endocrinol. Metab. 2004;89:4615-4619.
ABSTRACT | FULL TEXT  

Avandamet
Kunhiraman et al.
British Journal of Diabetes & Vascular Disease 2004;4:268-271.
ABSTRACT  

Improved Glycemic Control Without Weight Gain Using Triple Therapy in Type 2 Diabetes
Strowig et al.
Diabetes Care 2004;27:1577-1583.
ABSTRACT | FULL TEXT  

Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy
Sutinen et al.
Am. J. Physiol. Endocrinol. Metab. 2004;286:E941-E949.
ABSTRACT | FULL TEXT  

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis
Salpeter et al.
Arch Intern Med 2003;163:2594-2602.
ABSTRACT | FULL TEXT  

Early Combination Therapy With a Thiazolidinedione for the Treatment of Type 2 Diabetes
Kanzer-Lowis
The Diabetes Educator 2003;29:954-961.
 

Update on diabetes diagnosis and management
ROBERTSON et al.
Journal of the American Dental Association 2003;134:16S-23S.
ABSTRACT | FULL TEXT  

Thiazolidinediones and Blood Lipids in Type 2 Diabetes
van Wijk et al.
Arterioscler. Thromb. Vasc. Bio. 2003;23:1744-1749.
ABSTRACT | FULL TEXT  

Current Therapeutic Options in Type 2 Diabetes Mellitus: A Practical Approach
Sheehan
Clin Med Res 2003;1:189-200.
ABSTRACT | FULL TEXT  

PPARalpha /gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly
Ye et al.
Am. J. Physiol. Endocrinol. Metab. 2003;284:E531-E540.
ABSTRACT | FULL TEXT  

Acarbose Improves Glycemic Control in Overweight Type 2 Diabetic Patients Insufficiently Treated With Metformin
Phillips et al.
Diabetes Care 2003;26:269-273.
ABSTRACT | FULL TEXT  

Counseling Patients With Type 2 Diabetes and Insulin Resistance in the Outpatient Setting
Campbell and White
The Diabetes Educator 2002;28:938-957.
 

Biological Variation of Homeostasis Model Assessment-Derived Insulin Resistance in Type 2 Diabetes
Jayagopal et al.
Diabetes Care 2002;25:2022-2025.
ABSTRACT | FULL TEXT  

Initial Management of Glycemia in Type 2 Diabetes Mellitus
Nathan
NEJM 2002;347:1342-1349.
FULL TEXT  

Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes
Rosenstock et al.
Diabetes Care 2002;25:1529-1533.
ABSTRACT | FULL TEXT  

Ameliorated Hepatic Insulin Resistance Is Associated with Normalization of Microsomal Triglyceride Transfer Protein Expression and Reduction in Very Low Density Lipoprotein Assembly and Secretion in the Fructose-fed Hamster
Carpentier et al.
J. Biol. Chem. 2002;277:28795-28802.
ABSTRACT | FULL TEXT  

Metformin: An Update
Kirpichnikov et al.
ANN INTERN MED 2002;137:25-33.
ABSTRACT | FULL TEXT  

Time2Take on Risk: Report of a GSK symposium from Diabetes UK, Birmingham, March 13th 2002
British Journal of Diabetes & Vascular Disease 2002;2:s1-S5.
 

Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review
Inzucchi
JAMA 2002;287:360-372.
ABSTRACT | FULL TEXT  

{blacktriangledown}Pioglitazone and {blacktriangledown}rosiglitazone for diabetes
DTB 2001;39:65-68.
ABSTRACT | FULL TEXT  

A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes
Raskin et al.
Diabetes Care 2001;24:1226-1232.
ABSTRACT | FULL TEXT  

The failings of NICE
Rawlins et al.
BMJ 2001;322:489-489.
FULL TEXT  

Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 Diabetes
Phillips et al.
Diabetes Care 2001;24:308-315.
ABSTRACT | FULL TEXT  

Thiazolidinediones for type 2 diabetes
Glazer et al.
BMJ 2001;322:235-235.
FULL TEXT  

Nonhypoglycemic Effects of Thiazolidinediones
Parulkar et al.
ANN INTERN MED 2001;134:61-71.
ABSTRACT | FULL TEXT  

Review: Thiazolidinediones today
Bailey and Day
British Journal of Diabetes & Vascular Disease 2001;1:7-13.
ABSTRACT  

Additional articles abstracted in ACP Journal Club
Evid. Based Med. 2000;5:163-163.
FULL TEXT  

A new option in oral hypoglycemic therapy for type 2 diabetes mellitus
Farquhar
CMAJ 2000;163:1186-1186.
FULL TEXT  

Combination Oral Therapy for Patients with Type 2 Diabetes
JWatch General 2000;2000:6-6.
FULL TEXT